| Recommendations A: 31 (8.7%) | |
|---|---|
| Therapeutic group | DAA |
| Antiretroviral: 27/31 | Sofosbubir/Simeprevir: 4 Sofosbubir/Daclatasvir: 23 |
| Proton pump inhibitors: 2/31 | Sofosbubir/Simeprevir: 2 |
| Opioids: 1/31 Endothelin receptor antagonist: 1/31 | OBV/PTV/r + Dasabuvir: 1 Sofosbubir/Simeprevir: 1 |
| Recommendations B: 90 (25%) | |
| Antiretroviral: 8/90 | Sofosbubir/Simeprevir: 3 Sofosbubir/Daclatasvir: 5 |
| Benzodiazepines: 13/90 | Sofosbubir/Simeprevir: 9 OBV/PTV/r + Dasabuvir: 4 |
| Beta-blockers: 10/90 | Sofosbubir/Simeprevir: 6 Sofosbubir/Daclatasvir: 1 OBV/PTV/r + Dasabuvir: 3 |
| Calcium antagonists: 9/90 | Sofosbubir/Simeprevir: 6 Sofosbubir/Daclatasvir: 1 OBV/PTV/r + Dasabuvir: 2 |
| Renin-angiotensin system inhibitors: 8/90 | Sofosbubir/Simeprevir: 2 OBV/PTV/r + Dasabuvir: 6 |
| Statins and Fibrates: 8/90 | Sofosbubir/Simeprevir: 8 |
| Sulphonylurea: 5/90 | Sofosbubir/Simeprevir: 4 OBV/PTV/r + Dasabuvir: 1 |
| Proton pump inhibitors: 2/90 | OBV/PTV/r + Dasabuvir: 1 Sofosbuvir/Ledipasvir: 1 |
| Other: corticoids, antiplatelets, neuroleptics, endothelin receptor antagonists, antiepileptics, antiarrhythmics, SSRI, 5 alpha-reductase inhibitor, prokinetics, bisphosphonates: 27/90 | |